Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: jaybe who wrote (4309)	6/10/2016 12:06:22 AM
From: Biomaven	Respond to of 4474

I think the space is going to end up as a fight between alectinib and briga for front line. Briga is a bit better, but alectinib has a lead of over a year, and sometimes it is quite hard for a better drug to displace a good existing drug. It's crazy that docs still use criz at all, and ceritinib is not a good drug by comparison with briga or alectinib. The PFE drug will be reserved for a later line and might find some use. Anyhow that's my current take - we'll see how it all plays out.